大黄素
药理学
2019年冠状病毒病(COVID-19)
消炎药
汤剂
中医药
传统医学
化学
槲皮素
医学
生物化学
传染病(医学专业)
疾病
抗氧化剂
替代医学
病理
作者
Haiyu Xu,Shufen Li,Jiayuan Liu,Jinlong Cheng,Liping Kang,Weijie Li,Yute Zhong,Chaofa Wei,Lifeng Fu,Jianxun Qi,Yulan Zhang,Miaomiao You,Zhenxing Zhou,Chongtao Zhang,Haixia Su,Sheng Yao,Zhaoyin Zhou,Yulong Shi,Ran Deng,Qi Lv
标识
DOI:10.1073/pnas.2301775120
摘要
), as well as two inhibitors (glycyrrhisoflavone and licoisoflavone A) of the RNA-dependent RNA polymerase (RdRp). Meanwhile, three anti-inflammatory components, including licochalcone B, echinatin, and glycyrrhisoflavone, were identified in a SARS-CoV-2-infected inflammatory cell model. In addition, glycyrrhisoflavone and licoisoflavone A also displayed strong inhibitory activities against cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4). Crystal structures of PDE4 in complex with glycyrrhisoflavone or licoisoflavone A were determined at resolutions of 1.54 Å and 1.65 Å, respectively, and both compounds bind in the active site of PDE4 with similar interactions. These findings will greatly stimulate the study of TCMT-NDRD against COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI